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to reference "early stage" disease. However, no further detail related to stage is mentioned in the eligibility criteria described later in the manuscript. The authors do note eligible women are within 2-4 years of their diagnosis. I recommend revision to clarify what is meant by "early" in the abstract and to iterate whether any exclusion was made related to disease stage in description of participants on page 8. Also, in the Abstract, the authors note that the "primary outcome at baseline and 6 months" is verbal learning. Depending on allowable word count, a suggested revision would be, "The primary outcome (verbal learning) is measured at baseline and 6 months." I also recommend moving the sentence about MRI scans and blood sampling to be prior to the sentence describing what will be done at 18 months, as I believe MRI and blood sampling are being collected only at baseline and 6-month assessment time points. The Ethics and Dissemination section of the Abstract I may benefit from minor rewording. Perhaps: "Study results may impact usual care if physical exercise improves cognitive functioning for breast cancer survivors." Strengths and Limitations of the Study: I found a couple of grammatical issues in this section. In the second sentence, I suggest revising to "the study is designed not only to investigate the effect of exercise….". I found the last statement in this section to be unclear. I understand that results from a study involving only breast cancer survivors may not be generalizable to a broader patient population. But the current wording, "The present study might hamper generalizability to other patients with cancer outside the CNS" seemed a less clear way of communicating this message to the reader. Introduction: I recommend revising the second sentence in this section to "Research has shown that a portion of breast cancer survivors experience cognitive decline"…… The statement where percentages of the range of incidence are listed needs a reference citation. On page 7, second line "influence by" should be "influenced by". I suggest some rewording of the sentence starting in line 15/16 to "In another pilot study conducted during chemotherapy (n=17)…" Methods and Analyses, Design: The last sentence is a bit unclear. Rather than "the inclusion of the study started in December 2016", I suggest revising to "Recruitment for the study started in December 2016 and still is on-going". I noted that on page 8 the authors state that eligibility includes "moderate to lower performance on neuropsychological testing". However, on page 9 they refer to "patients performing lower than expected" and note a z-score of 1 under or above the mean of a control group on at least two tests of different domains. I was confused as to why participants with a z-score 1 above the mean of a control would be considered low performing. On page 9, line 8, "contra indications" has an extra space. I was a bit confused by the wording related to endocrine therapy and cognitive concerns. Again, this may be an English language issue. Is the authors' intention to indicate that some types of endocrine therapy may be more likely than others to cause cognitive issues? If so, I think the wording could be revised to be more clear on this point. I agree that cognitive problems can be exacerbated by anxiety, depression, and fatigue. However, I would suggest a better rationale for only accepting women whose self-report was confirmed by neuropsychological performance, was to enroll women with more severe symptoms and therefore have more likelihood of seeing an improvement with the intervention. Much evidence exists to support a lack of correlation between objective and subjective testing due to the ability of women to compensate for their deficits, thereby performing within normal limits but exerting more cognitive effort to do so. I found Table 1 a bit confusing. The title implies that traditional tests will be indicated along with the online equivalents. I don't see any traditional tests listed? Is the Wordlist Learning supposed to be a substitute for the HVLT-R? I strongly recommend development of a table/grid outlining the assessment timepoints (including the initial screening with the on-line cog tests) and instruments/data collected at each to help the reader get the overall picture of the study. These types of tables commonly are requested by IRBs to assist study staff as well as participants to have a clear picture of when the study procedures are due. On page 9 a first consent is mentioned for the administration of the online battery. Where does this written consent take place? Where does the online battery take place? Is special equipment needed for the motor functioning test? Exercise intervention: I think a brief description of what Nordic walking is would be helpful. I see that poles are used, but how else would this compare to the power walking? Actually, a brief description of power walking also would be useful. Additionally, a description what is meant by "pragmatic" 15-and 20 repetition maximum tests would help with clarity. And, why was 20 selected for the first 4 weeks and 15 selected for the other time points? Table 2 is a bit unclear as well. The table seems to imply the RM is only done twice instead of every 4 weeks as noted in the narrative. Also, the authors use the heading of "endurance" however the term "aerobics" is used in the narrative. I recommend consistency throughout to help with clarity. Table 2 also includes the term "hoover". I recommend some explanation for the reader of that term as it is unfamiliar. I was very happy to see that Controls are offered a supervised exercise program at the study conclusion. Study endpoints: I was surprised at the selection of the two symptom severity questions (and symptom interference) from the MDASI for Multiple Myeloma when the study is focused on breast cancer. Was there a rationale for this? Additionally, there are more robust self-report instruments for cognitive issues (such as the FACT-Cog, and the PROMIS Cognitive General concerns and abilities short forms). I would like to see the rationale for the instrument choice. A heading indicating which outcome measures are being collected at baseline and 6 months would be helpful (like the one highlighting the 18 months assessments on page 17). Even though this is mentioned in the narrative at the top of page 14, I missed it on the first read. PROs: I was a little unclear about whether the Actigraph data were being collected during the final seven days of the intervention period, or the seven days after the conclusion of the intervention. Anthropometrics: Are the two waist/hip circumference measurements taken at the same time to calculate the average? What was the rationale for an immediate repeat? Analyses: I think I am understanding the authors' intention related to the intention to treat analysis. Am I correct that ITT only is employed for the analyses not related to the MRI results unless 80% adherence? And, the last sentence on page 18 re: long-term effects mixed modeling was unclear to me. Which two follow-up measurements were being referenced here? Ethics: On page 19 the authors indicate they expect more incidental findings than those from studies with healthy people. I assumed this may be due to discovery of metastases. However, the authors go on to say that these findings likely will not have clinical consequences and include a wait-and-see policy. I recommend revising with additional information to clarify what the authors are expecting here.
VERSION 1 -AUTHOR RESPONSE
Reviewer: 1 Introduction: include the neuroimaging study of S Deprez (J Clin Oncol 2014) Authors' answer:
We included the study of Deprez and added the following to the introduction on page 5, line 88:
"Using functional magnetic resonance imaging (fMRI), a study of Deprez [24] reported decreased brain activation during multitasking of chemotherapy-treated patients, which was associated with an increase in subjective cognitive complaints." Design: consider to stratify for menopausal state and endocrine therapy as both may influence cognitive functioning.
Authors' answer:
We agree that endocrine therapy might influence cognitive functioning. Therefore, we stratified the randomisation by use of endocrine therapy (yes or no). We also acknowledge that menopausal state might influence cognitive functioning. We did not stratify for this factor to minimize the number of stratification factors to increase random allocation. Furthermore, age is also a stratification factor which may also partly cause an equal distribution of menopausal status over the intervention and control group.
Reviewer: 2 Abstract: In the Methods and analytics section the authors refer to "early" breast cancer patients. I believe their intention here may be to reference "early stage" disease. However, no further detail related to stage is mentioned in the eligibility criteria described later in the manuscript. The authors do note eligible women are within 2-4 years of their diagnosis. I recommend revision to clarify what is meant by "early" in the abstract and to iterate whether any exclusion was made related to disease stage in description of participants on page 8.
We agree that we are not clear by our in-and exclusion criteria. We include breast cancer patients with stage 1, 2 and 3, but not patients with stage 4 (distant metastases). We acknowledge that 'early stage' disease normally means stage 1 and therefore we removed 'early' in the abstract. Furthermore, we included this stage 1-3 in our inclusion criteria.
Also, in the Abstract, the authors note that the "primary outcome at baseline and 6 months" is verbal learning. Depending on allowable word count, a suggested revision would be, "The primary outcome (verbal learning) is measured at baseline and 6 months." Authors' answer:
We thank the reviewer for this suggestion, we adjusted it accordingly.
I also recommend moving the sentence about MRI scans and blood sampling to be prior to the sentence describing what will be done at 18 months, as I believe MRI and blood sampling are being collected only at baseline and 6-month assessment time points.
It is correct that MRI and blood sampling only are collected at baseline and after 6 months. We moved the sentence accordingly.
The Ethics and Dissemination section of the Abstract may benefit from minor rewording. Perhaps: "Study results may impact usual care if physical exercise improves cognitive functioning for breast cancer survivors."
We changed the sentence in the Ethics and Dissemination section accordingly.
Strengths and Limitations of the Study: I found a couple of grammatical issues in this section. In the second sentence, I suggest revising to "the study is designed not only to investigate the effect of exercise….".
We thank the reviewer for the grammatical comments. We adjusted the sentence accordingly.
I found the last statement in this section to be unclear. I understand that results from a study involving only breast cancer survivors may not be generalizable to a broader patient population.
But the current wording, "The present study might hamper generalizability to other patients with cancer outside the CNS" seemed a less clear way of communicating this message to the reader.
We changed the sentence in the ethics and dissemination section: "The present study might hamper generalizability to a broader patient population who experience cognitive problems after cancer." Introduction: I recommend revising the second sentence in this section to "Research has shown that a portion of breast cancer survivors experience cognitive decline"…… Authors' answer:
We thank the reviewer for the suggestion, we changed it accordingly.
The statement where percentages of the range of incidence are listed needs a reference citation.
We apologize that the reference citations were missing, we added this in the manuscript.
On page 7, second line "influence by" should be "influenced by".
We changed it accordingly.
I suggest some rewording of the sentence starting in line 15/16 to "In another pilot study conducted during chemotherapy (n=17)…" Authors' answer:
We changed the sentence: "In another pilot study conducted during chemotherapy (n=17), the strength exercise group showed higher performance on concentration and verbal memory compared to the control group."
Methods and Analyses, Design: The last sentence is a bit unclear. Rather than "the inclusion of the study started in December 2016", I suggest revising to "Recruitment for the study started in December 2016 and still is on-going".
We thank the reviewer for the suggestion. We changed the sentence accordingly.
I noted that on page 8 the authors state that eligibility includes "moderate to lower performance on neuropsychological testing". However, on page 9 they refer to "patients performing lower than expected" and note a z-score of 1 under or above the mean of a control group on at least two tests of different domains. I was confused as to why participants with a z-score 1 above the mean of a control would be considered low performing.
We are sorry for the confusion. In some tests, the Z-score above the mean implicates worse performance. For example, if the reaction time is long, the score of the test is high. We changed the sentence on page 10, line 191: "Patients performing lower than expected, i.e. a worse z-score of at least 1 compared to a control group, on at least two tests of the different domains (learning and memory, attention and working memory, processing speed, executive functioning, motor functioning) compared to the normative data of a healthy female population by age, are eligible for inclusion." On page 9, line 8, "contra indications" has an extra space.
We changed it into contraindications.
I was a bit confused by the wording related to endocrine therapy and cognitive concerns. Again, this may be an English language issue. Is the authors' intention to indicate that some types of endocrine therapy may be more likely than others to cause cognitive issues? If so, I think the wording could be revised to be more clear on this point.
We are sorry for the confusion, we indeed meant what you are stated. It may be that some types of endocrine therapy are more likely than other to cause cognitive issues or different types may cause different issues. As this is not clear yet, we decided not to include patients who switch or stop endocrine therapy during the study period or four months prior to the start of the study. We changed the sentences on page 9, line 173: "The latter is chosen since we do not know if different endocrine therapies may differ in their potential impact on cognitive performance." I agree that cognitive problems can be exacerbated by anxiety, depression, and fatigue. However, I
would suggest a better rationale for only accepting women whose self-report was confirmed by neuropsychological performance, was to enroll women with more severe symptoms and therefore have more likelihood of seeing an improvement with the intervention. Much evidence exists to support a lack of correlation between objective and subjective testing due to the ability of women to compensate for their deficits, thereby performing within normal limits but exerting more cognitive effort to do so.
We thank the reviewer for this thoughtful comment on this complex issue. Indeed, multiple studies (inside and outside oncology) have shown a low correlation between tested cognitive functioning and self-reported cognitive functioning. Multiple studies have also indicated that self-perceived cognitive functioning is often rather strongly related to other symptoms such as distress. We are aware that fMRI studies have pointed to the possibility that normal performance on neuropsychological tests may be achieved by abnormal effort, which is expressed by the patients in their cognitive complaints.
The aim of our mechanistic study is to investigate if and how exercise can diminish chemotherapyrelated cognitive problems. Because of this research question, we believe that the method of choice for assessing cognitive problems is in this case both self-reported and tested cognitive functioning. If we would rely on self-reported cognitive complaints alone without information of tested cognitive functioning, it is possible that these self-reported cognitive complaints are driven principally for example by anxiety, which would require a different intervention. Our intervention would not diminish these complaints -not because they are not severe enough, but because they have a different origin.
I found Table 1 a bit confusing. The title implies that traditional tests will be indicated along with the online equivalents. I don't see any traditional tests listed? Is the Wordlist Learning supposed to be a substitute for the HVLT-R? I strongly recommend development of a table/grid outlining the assessment timepoints (including the initial screening with the on-line cog tests) and instruments/data collected at each to help the reader get the overall picture of the study. These types of tables commonly are requested by IRBs to assist study staff as well as participants to have a clear picture of when the study procedures are due.
We agree that the title is unclear, since the traditional tests are not stated in the table in this manuscript. Therefore, we changed the title. Furthermore, we included Figure 1 in our Manuscript and included the following sentences on page 8, line 156: "The PAM (Physical Activity & Memory) study is a RCT with two study groups, i.e. a 6-month exercise intervention group and a control group (see figure 1 for an overview)." On page 9 a first consent is mentioned for the administration of the online battery. Where does this written consent take place? Where does the online battery take place? Is special equipment needed for the motor functioning test?
Authors' answer:
The written consent for the online test battery is signed at home and returned by post to the study team. Thereafter, the study team sends an email with a link to the online test. The patients complete the test battery online at home. Patients receive instructions for the correct execution of the tests, e.g. they need a quiet place without disturbances, a computer or laptop with a mouse (Feenstra et al 2017a) . We explained this in more detail on page 9, line 187: "After the telephone screening, eligible women sign written informed consent specifically for performing a full online neuropsychological test battery: the Amsterdam Cognition Scan (Feenstra et al. 2017b ) and sent the original written informed consent to the study team by post. The patients receive an email with instructions to conduct the test battery (Feenstra et al. 2017a) ." Exercise intervention: I think a brief description of what Nordic walking is would be helpful. I see that poles are used, but how else would this compare to the power walking? Actually, a brief description of power walking also would be useful.
We included the following sentences on page 11, line 231:
"Patients choose whether they prefer Nordic or power walking. By using poles for Nordic walking, the technique will focus more on the trunk and arms to reduce the load on the legs (Wilson et al, 2001 ). Power walking consists of a fast walking pace including an active upper body movement. We choose for these types of walking since these are more effective to increase cardiovascular fitness compared to standard walking ( We added the following sentences to be more clear: "The intensity of the strength exercises is determined by pragmatic 15 -and 20 repetition maximum (RM, the maximum weight at which a muscle group can perform repetitions) tests and repeated every 4 weeks (Table 2) . A 15-and 20 RM is assessed instead of a 1-RM test, since this is less sensitive for injuries and easier for the physical therapist to use (without making use of calculations)." Furthermore, we choose 15RM for the later time points in the exercise program to increase the intensity of the strength exercises. Table 2 is a bit unclear as well. The table seems to imply the RM is only done twice instead of every 4 weeks as noted in the narrative. Also, the authors use the heading of "endurance" however the term "aerobics" is used in the narrative. I recommend consistency throughout to help with clarity. Table 2 also includes the term "hoover". I recommend some explanation for the reader of that term as it is unfamiliar.
We changed table 2 accordingly. Since hoover is the same as planking, we also made an adjustment to be more clear I was very happy to see that Controls are offered a supervised exercise program at the study conclusion.
We thank the reviewer for the kind words.
Study endpoints: I was surprised at the selection of the two symptom severity questions (and symptom interference) from the MDASI for Multiple Myeloma when the study is focused on breast cancer. Was there a rationale for this? Additionally, there are more robust self-report instruments for cognitive issues (such as the FACT-Cog, and the PROMIS Cognitive General concerns and abilities short forms). I would like to see the rationale for the instrument choice.
We choose the MDASI-MM instead of other questionnaires, because the questions of the MDASI-MM have a better correlation with the neuropsychological tests than the before mentioned questionnaires as the FACT-Cog. Furthermore, the MDASI-MM does not only focus on the frequency of the symptoms, but also on the impact of the cognitive problems.
A heading indicating which outcome measures are being collected at baseline and 6 months would be helpful (like the one highlighting the 18 months assessments on page 17). Even though this is mentioned in the narrative at the top of page 14, I missed it on the first read.
We included a heading on page 12, line 250: 'Baseline and 6-month follow up measurements'.
PROs: I was a little unclear about whether the Actigraph data were being collected during the final seven days of the intervention period, or the seven days after the conclusion of the intervention.
We changed the sentence to avoid confusion on page 15, line 319:
"In addition, all participants wear an accelerometer (Actigraph) for 7 days at the beginning of the intervention period (before the start of the exercise program) and during the final 7 days of the intervention period." Anthropometrics: Are the two waist/hip circumference measurements taken at the same time to calculate the average? What was the rationale for an immediate repeat?
The measurements were indeed taken at the same moment and average was calculated afterwards. The World Health Organization recommends doing the measurements twice to minimalize measurement error.
Waist circumference and waist-hip ratio: report of a WHO expert consultation, Geneva, 8-11 December 2008.
Analyses: I think I am understanding the authors' intention related to the intention to treat analysis. Am I correct that ITT only is employed for the analyses not related to the MRI results unless 80% adherence?
